KW 4490

Drug Profile

KW 4490

Alternative Names: KW-4490

Latest Information Update: 18 Dec 2008

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Antiasthmatics; Cyclohexanecarboxylic acids; Dioxanes
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 27 Sep 2004 Discontinued - Phase-II for Asthma in France (PO)
  • 27 Sep 2004 Discontinued - Phase-II for Asthma in United Kingdom (PO)
  • 15 Jun 2004 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top